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A B S T R A C T
We assessed the diagnostic efficacy of plasma Myeloperoxidasis (MPO) alone or in combination with cardiac troponin
I (cTnI) for detecting ACS in patients presenting with chest pain initiating within 24 h before the hospital admission. In
this prospective cohort study were included all respondents who have visited outpatient clinic of internal diseases, Uni-
versity Hospital Mostar because of chest pain and suspected acute coronary syndrome within 24 h of the onset of the pe-
riod of 6 months and the total sample consisted of 114 patients. Troponin and myeloperoxidase were significantly posi-
tively correlated at the beginning of treatment, myeloperoxidase was significantly positively associated with adverse
cardiovascular events during hospitalization and myocardial infarction (p<0.05), with the regression analysis did not
show a significant predictor in the development of myocardial infarction (p>0.05). Sensitivity of myeloperoxidase as a
valid test detection of myocardial infarction at baseline was 0.15 and specificity was 0.85, suggesting good diagnostic
value usable in the clinical practice.
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Introduction
Acute myocardial ischemia is one of the main causes
of chest pain and accurate identification is of utmost im-
portance to avoid unnecessary hospital admissions and
inadequate hospital releases1–4. Early diagnosis of acute
coronary syndrome (ACS) is frequently a challenging
task, while immediate risk stratification remains crucial
for the prompt implementation of appropriate therapy in
this setting5–10. The correct final diagnosis is supported
by the type of pain, electrocardiogram (ECG) and release
pattern of myocardial necrosis markers11,12. Many pa-
tients with chest pain have normal levels of creatine
kinase isoenzymes or troponins at presentation but sub-
sequently have a myocardial infarction, require
revascularization, or die within six months13–15. However,
the prolonged release pattern of troponins, well-estab-
lished biomarkers of myocardial necrosis, and limited
sensitivity of the routine troponin assay make it difficult
to diagnose acute coronary syndrome (ACS) at an early
stage5–10. Additional biochemical measures, ideally based
on the pathophysiology of plaque vulnerability, are ne-
eded13–15. Employing markers that increase rapidly after
the symptom onset may enhance triage and therapeutic
decision-making in patients suspected for ACS5–10. In-
flammation has been linked to all stages of the develop-
ment of vulnerable plaque, from initial lipid deposition to
plaque rupture and its thrombotic complications13–15,
and extensive monocyte and neutrophil infiltration is
seen in fissured, thrombosed plaques in patients with
acute coronary syndromes16,17.
Accumulating evidence suggests that Activation of
leukocytes, and in particular polymorphonuclear neutro-
phils with concomitant release of the heme-enzyme my-
eloperoxidase (MPO), is closely linked to coronary plaque
injury, and thus an early event in acute coronary dise-
ase15,18–20. Myeloperoxidase has been linked to the devel-
opment of lipid-laden soft plaque14,15, the activation of
protease cascades affecting the stability and thrombo-
213
Received for publication February 10, 2014
genicity of plaque16,17. In fact, MPO demonstrated to
promote endothelial dysfunction by oxidizing endothelial
nitric oxide21–26, leading to vasoconstriction27,28 and oxi-
datively converting low-density and high-density lipo-
proteins to proatherogenic derivatives14,29. Also, MPO
has been shown to activate matrix metalloproteinases,
enzymes involved in plaque rupture, and myocardial
fibrosis30. Moreover, MPO adversely affected myocardial
remodeling, thereby adding to its potential mechanistic
involvement in heart failure31. It has been established as
a valuable marker of cardiovascular disease that in-
dependently predicts the risk of patients presenting with
chest pain6,5. The fact that MPO release from leukocytes
is connected to plaque rupture stimulated investigations
assessing the clinical value of MPO plasma levels as early
markers of ACS20. These retrospective analyses using a
single time point determination of MPO suggested, that
MPO is a prognostic indicator within the first hours after
symptom onset, in which markers of myocardial necrosis
like troponin and creatinine kinase isoenzymes are still
non-elevated and lack diagnostic or prognostic infor-
mation, respectively20,32. Indeed, recent studies indicated
that the increase of MPO plasma levels precedes myo-
cardial tissue injury20 and suggested a potential for MPO
as a diagnostic marker with high negative predictive
value complementing troponins by facilitating to rule out
ACS in patients presenting early after chest pain onset33.
However, other studies failed to show a diagnostic utility
of MPO plasma levels in ACS patients10,34. Moreover, it
has been shown that MPO is an independent predictor of
long-term major cardiovascular events in patients pre-
senting with chest pain, acute myocardial infarction and
a variety of other cardiovascular disorders1,2,5–7. Whether
MPO has the potential to evolve as an additive diagnostic
tool in patients admitted with suspected myocardial in-
farction should be evaluated5,6,9,20,32,35,36.
Materials and Methods
According to its structure this is a cross-sectional
study. The study included subjects who arrived at the
admission department of the Clinic for Internal Me-
dicine, University Clinical Hospital Mostar because of
chest pain and suspected acute coronary syndrome with-
in 24 hours of onset of pain, in the period of six months,
from December 1, 2011 to June 31, 2012. This study
obtained the approval of the ethical acceptability from
the Ethics Committee of the University Clinical Hospital
Mostar, and the consent and permission to conduct the
testing from the head of the Department of Internal
Medicine SKB Mostar. Each patient was asked to sign a
consent form before being included in the study.
At admission department, after taking the anamne-
sis, physical examination and ECG insight patients were
divided into three groups: 1) Patients with myocardial
infarction with ST segment elevation. 2) Patients with
acute coronary syndromes without ST segment eleva-
tion, some of which had a number of changes in the ECG
(ST segment depression, T wave changes), while others
had no changes in the ECG. Subsequently, based on the
concentration of trponin the diagnosis of myocardial
infarction without ST elevation or unstable angina pec-
toris was set. 3) In a certain number of respondents
problems were not a result of acute coronary syndrome
but of stable angina pectoris or were not a consequence
of coronary heart disease. The study included a total of
114 patients. 77 (67.5%) cases involved men and 37
(32.5%) cases involved women (c2=14.035, df=1, p<
0.001). The average age of the patients was 64.8±13.6
years. The youngest participant was 20 and the oldest 90
years. At the age of up to 50 years were 12 (10.5%)
patients, aged between 50–64 years 46 (40.4), while at
the age of 65 years or more were 56 (49.1%) patients
(c2=27.310, df=2, p<0.001). Blood samples were taken
within 24 hours of the onset of pain on arrival at the ad-
mission department from all patients who were due to
chest pain and suspected ACS, then on the seventh day
and a month after the onset of chest pain. The catalytic
activity of myeloperoxidase (MPO) was measured in the
plasma of patients using chemiluminescent micropar-
ticle immunoassay (CMIA) on an Abbott Architect i2000
Analyzer. It is an immunoassay of two steps to determine
the catalytic activity of NGAL. In the first step, the MPO
present in the sample binds to the paramagnetic micro-
particle-labeled anti-MPO antibodies. After washing, in
the second step, the binding of anti-MPO antibody lab-
eled acridine results after washing in chemiluminescent
signal the intensity of which is proportional to the cata-
lyst concentration of MPO in the sample.
Statistics
Statistical tests were used to study the sensitivity,
specificity, positive and negative predictive value. For the
analysis of categorical variables c2-test was used. Para-
metric tests were used to test differences of symmet-
rically distributed variables between the investigated
groups, while the asymmetrically distributed variables
were tested with nonparametric tests (Mann-Whitney U,
Kruskal Wallis).
Results
The most common diagnosis at admission was myo-
cardial infarction (STEMI+NSTEMI), while the fewest
number of cases was unstable angina pectoris (c2=
16.947, df=3, p<0.001). In 7% of respondents have expe-
rienced fatal outcome (c2=84.246, df =1, p<0.001) (Ta-
ble 1).
After a complete analysis of correlation between the
predictive value of myeloperoxidase in blood and the
final outcome of the disease, we analyzed the sensitivity,
specificity, and positive and negative value of myeloper-
oxidase in all observed time points of measurement. In
the beginning of treatment for myeloperoxidase, the as-
say sensitivity was 0.15. The specificity of myelopero-
xidase as a valid test in the overall recognition of myo-
cardial infarction was 0.85, while the positive predictive
value was 0.52, and negative predictive value was 0.49
(Table 2).
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On the seventh day treatment sensitivity of myelo-
peroxidase as a valid test in the overall recognition of
myocardial infarction was 0.07, specificity was 0.92. The
positive predictive value was 0.50, while the negative
predictive value was 0.51 (Table 3).
On the 30th day treatment sensitivity of myeloper-
oxidase as a valid test in the overall recognition of myo-
cardial infarction was 0, the specificity was 0.98. The
positive predictive value was 0, while the negative pre-
dictive value was 0.50 (Table 4).
Discussion
As already mentioned, in the analysis of correlation
between myeloperoxidase and AMI and adverse cardio-
vascular events during hospitalization, in addition to
correlation and this predictive value in the development
of myocardial infarction we also evaluated the value of
MPO as a valid test of detection of myocardial infarction
through its sensitivity, specificity and positive and nega-
tive predictive value. Sensitivity of myeloperoxidase in
this recognition in the beginning of treatment was 0.15.
Its specificity was 0.85. while the positive predictive
value was 0.52, and negative predictive value was 0.49.
With a longer period of hospitalization MPO sensitivity
in identifying myocardial infarction was falling, while
the specificity was increasing. In accordance with these
results, the findings of previous studies such as multi-
-center studies of Volker and his colleagues37 show that
MPO gives no diagnostic information for patients with
symptoms of acute chest pain, when added to the sen-
sitive troponin I, as both sensitivity and specificity of
MPO in relation to troponin was lower. Because of the
high negative predictive value achieved in his research,
Volker hypothesized that the MPO could become a useful
marker for the exclusion of AMI at an early stage and as
D-dimer in patients with suspected pulmonary embo-
lism, it can help for faster triage of patients with acute
pain chest. However, results of previous studies differ
significantly among themselves and similar hypotheses
are relatively unreliable. Thus, for instance Sawicki and
colleagues38 found in their study that the MPO showed
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TABLE 1
DISTRIBUTION OF RESPONDENTS TO DIAGNOSIS AND
TREATMENT OUTCOME
Variables N % c2 p
Dijagnose 16.947 <0.001
Stable angina pectoris 43 37.7






NSTEMI – non-ST segment elevation myocardial infarction
STEMI – ST segment elevation myocardial infarction
TABLE 2
DISTRIBUTION OF ELEVATED MPO IN THE BEGINNING OF TREATMENT IN RELATION TO THE FINAL OUTCOME OF THE DISEASE
Myeloperoxidas levels in
the beginning of treatment
Diagnosed miocardial infarct Not diagnosed miocardial infarct Total
N (%) N (%) N (%)
Elevated 9 15.5 8 14.3 17 14.9
Not elevated 49 84.5 48 85.7 97 85.1
TABLE 3
DISTRIBUTION OF ELEVATED MPO ON THE SEVENTH DAY OF TREATMENT COMPARED TO THE FINAL OUTCOME DISEASE
The level of myeloperoxidase on
the seventh day of treatment
Diagnosed myocardial infarction
Not diagnosed with myocardial
infarction
Total
N (%) N (%) N (%)
Elevated 4 7.5 4 7.1 8 7.3
Not elevated 49 92.5 52 92.9 101 92.7
TABLE 4
DISTRIBUTION OF ELEVATED MYELOPEROXIDASE ON THE 30TH DAY OF TREATMENT COMPARED TO THE FINAL OUTCOME DISEASE
The level of myeloperoxidase
on the 30th day of treatment
Diagnosed myocardial
infarction
Not diagnosed with myocardial
infarction
Total
N (%) N (%) N (%)
Elevated 0 7.5 1 1.8 1 0.9
Not elevated 53 100.0 54 98.2 107 99.1
excellent specificity and very good sensitivity in patients
with ACS, and a much better diagnostic efficacy in pati-
ents with unstable angina and non – ACS patients com-
pared with troponin. On the other hand, in relation to all
above studies MPO sensitivity in this study was ex-
tremely low, and the specificity was significantly higher
and relatively close to troponin specificity. Despite the
studies in which the MPO proved to be a promising
biomarker, Peacocck and his colleagues39 proved that the
MPO has limited clinical use in the intensive care units.
They showed that the MPO is a poor diagnostic tool in
patients with suspected ACS.
The results of this study and the results of previously
conducted studies worldwide show marked variations in
each of the studied objectives of this study, starting from
the correlation between the predictor values of myelo-
peroxidase and myocardial infarction and adverse cardio-
vascular events to the quality of myeloperoxidase as a
diagnostic tool in the early identification of myocardial
infarction and the difference in the level of myeloper-
oxidase depending on the diagnostic entity. The reason
for these differences in results can be different metho-
dological principles of research, different creation of the
test sample as well as different size of the study po-
pulation. The reasons can be not only methodological
frameworks but also a variety of demographic charac-
teristics of the studied populations. Variations on this
scale require additional studies the methodological struc-
ture of which will to be directed not to broad spectrum of
issues related to myeloperoxidase and its role, but spe-
cifically directed, increasing the size of the test sample in
order to reduce discrepancies in the results, and the
results could be more reliable.
Conclusion
Patients with normal troponin and myeloperoxidase
have a reduced likelihood of developing myocardial infar-
ction and subsequent cardiovascular events during hos-
pitalization. The level of myeloperoxidase in the regres-
sion analysis did not show a significant predictor in the
development of myocardial infarction during hospita-
lization, but is a significant predictor for the develop-
ment of adverse cardiovascular events.
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DIJAGNOSTI^KA VRIJEDNOST MIJELOPEROKSIDAZE U BOLESNIKA SA SUMNJOM
NA AKUTNI KORONARNI SINDROM
S A @ E T A K
Ispitivali smo dijagnosti~ku u~inkovitost plazmatske MPO pojedina~no ili u kombinaciji sa sr~anim troponinom I
(cTnI) za otkrivanje ACS kod bolesnika s bolovima u prsima koji po~inju unutar 24 sati prije prijema u bolnicu. U ovo
prospektivno kohortno istra`ivanje su uklju~eni svi ispitanici koji su se javili u prijemnu ambulantu Klinike za unu-
tarnje bolesti SKB Mostar zbog bolova u prsima i sumnje na akutni koronarni sindrom unutar 24 sata od nastupa
bolova u razdoblju od 6 mjeseci, s ukupnim uzorkom od 114 pacijenata. Troponin i mijeloperoksidaza su zna~ajno pozi-
tivno povezene na po~etku lije~enja, mijeloperoksidaza je zna~ajno pozitivno povezana s ne`eljenim kardiovaskularnim
doga|ajima tijekom hospitalizacije i infarktom miokarda (p<0,05), pri ~emu se u regresijskoj analizi nije pokazala kao
zna~ajan prediktor u razvoju infarkta miokarda (p>0,05). Osjetljivost mijeloperoksidaze u prepoznavanju infarkta mio-
karda na po~etku je bila 0,15, a specifi~nost 0,85, {to upu}uje na dobru dijagnosti~ku vrijednost upotrebljivu u klini~koj
praksi.
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